DAVITA INC
DVANYSETrading Snapshot
- Day Range
- $173.45 β $176.19
- 52-Week Range
- $101.00 β $247.49
- Volume
- $2.49B
- Avg Volume
- $2.15B
- Shares Outstanding
- 64.2M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $13.64B
- Last Q Revenue
- $3.55B
- P/E Ratio
- 15.1
- P/S Ratio
- 0.8x
- EPS (TTM)
- $13.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.1%
Why Investors Own DVA
- βHigh-growth profile β revenue up +57.1% YoY with expanding US Equity exposure.
- βHealthy economics β 72% gross margin and 30% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DAVITA INC
DVAAbout DAVITA INC
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.
DaVita reported double-digit EPS growth in the second quarter. Berkshire Hathaway owns roughly 45% of DaVita stock.

DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.

3 Surging Stocks That Don't Need the AI Boom to Keep Winning
With AI companiesβand related chip stocksβdriving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momen

DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) closed the most recent trading day at $193.86, moving +1.55% from the previous trading session.

Warren Buffett, Donald Trump Bet on Same 17 Stocks β Some Might Surprise You
President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.

A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 vs Price $189.32
On September 14, 2026, DaVita Inc (DVA) shares rose 4.3% to $189.32, reflecting strong momentum as the stock trades within a 52-week range of $101.00 to $247.49